Saturday 17 October 2026
Export TARS’s income statement to Excel — free account
Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024. In the quarter to June 2026, revenue grew 69.4%, EPS grew 10.4%, free cash flow grew 288.1% and total debt was flat, each against the same quarter a year earlier.
68.07
2.92
−4.11%
Follow TARS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Piotroski F-Score |
5 | 4 | 1 | — | — | — | — | — | — |
P/S ratio |
7.58 | 11.38 | 21.58 | 13.57 | 8.11 | — | — | — | — |
Altman Z-Score |
9.54 | 7.17 | 3.20 | 5.84 | 23.62 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
2.84 | 1.09 | 1.81 | 8.43 | 19.10 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 146.26 | — | — | — | — |
P/Operating CF |
176.99 | (93.87) | (15.06) | (32.65) | (38.15) | — | — | — | — |
Beneish M-Score |
(1.78) | 5.07 | 3.48 | 73.87 | — | — | — | — | — |
P/B ratio |
9.96 | 9.27 | 3.01 | 1.84 | 2.77 | — | — | — | — |
Price to Tangible BV |
10.18 | 9.63 | 3.07 | 1.84 | 2.77 | — | — | — | — |
EV/Sales |
6.81 | 10.18 | 14.38 | 6.02 | 5.11 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(247.04) | (22.43) | (3.36) | (3.21) | 77.70 | — | — | — | — |
EV/FCF |
(98.24) | (19.90) | (3.32) | (3.18) | 92.10 | — | — | — | — |
Quick Ratio |
3.72 | 4.21 | 6.64 | 14.30 | 14.98 | 31.22 | 70.83 | 13.29 | — |
Current Ratio |
3.85 | 4.43 | 6.93 | 14.61 | 15.33 | 31.68 | 70.85 | 13.31 | — |
Net Debt/EBITDA |
4.66 | 1.78 | 1.36 | 3.12 | 14.82 | 6.27 | 13.70 | 1.76 | — |
Debt/Assets |
12.89% | 19.06% | 11.23% | 8.53% | 0.33% | 0.32% | 0.17% | 0.00% | 0.00% |
Debt/Equity |
0.21 | 0.32 | 0.15 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.96 | 0.57 | 0.07 | 0.13 | 0.33 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.19 | 0.72 | 0.86 | 0.79 | (0.27) | 0.79 | 0.79 | 0.90 | — |
Capex/Depreciation |
3.21 | 2.62 | 2.89 | 0.74 | (0.97) | (1.85) | (2.36) | 0.00 | — |
Interest Coverage |
(7.94) | (15.36) | (42.78) | (28.52) | (337.69) | (143.61) | — | (84.37) | — |
| (23.39%) | (54.83%) | (69.71%) | (34.53%) | (8.31%) | (33.52%) | 126.92% | 35.85% | — | |
| (14.14%) | (35.97%) | (55.09%) | (30.53%) | (7.88%) | (23.28%) | (15.39%) | (110.42%) | — | |
ROIC |
0.00% | (1,506.21%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(16.66%) | (41.51%) | (61.58%) | (29.44%) | (8.37%) | (16.17%) | (8.14%) | (59.68%) | — |
Average Days of Receivables |
70.44 | 95.88 | 370.59 | 50.64 | 0.59 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
14.25% | 29.18% | 288.37% | 165.11% | 73.14% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
94.67% | 129.71% | 623.03% | 174.11% | 44.54% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.01 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.24% | 15.20% | 113.66% | 52.14% | 14.83% | 0.00% | 0.00% | — | — |
Graham Net Nets |
0.09 | 0.10 | 0.32 | 0.54 | 0.35 | — | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(1.98%) | (5.60%) | (23.02%) | (17.68%) | (2.93%) | — | — | — | — |
Free Cash Flow Yield |
(0.92%) | (4.49%) | (20.09%) | (13.95%) | 0.68% | — | — | — | — |
Revenue per Share |
10.80 | 4.87 | 0.59 | 1.05 | 2.77 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.30) | (2.21) | (4.00) | (1.99) | 0.18 | (3.41) | (1.55) | (0.06) | — |
Capex per Share |
(0.24) | (0.17) | (0.19) | (0.02) | (0.03) | (0.07) | (0.07) | 0.00 | — |
Free Cash Flow per Share |
(0.53) | (2.38) | (4.19) | (2.01) | 0.15 | (3.48) | (1.63) | (0.06) | — |
Cash per Share |
10.00 | 7.75 | 7.74 | 8.82 | 8.36 | 27.09 | 24.53 | 0.12 | — |
Shareholders Equity per Share |
8.22 | 5.97 | 6.70 | 7.84 | 8.11 | 26.74 | 24.29 | 0.11 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
8.22 | 5.97 | 6.70 | 7.84 | 8.11 | 26.74 | 24.29 | 0.11 | — |
Free Cash Flow |
(22.31) | (89.59) | (122.99) | (49.54) | 3.16 | (21.59) | (3.85) | (1.18) | — |
Working Capital |
387.09 | 276.09 | 219.20 | 209.95 | 164.47 | 165.27 | 57.21 | 2.20 | — |
Capital Expenditures |
(9.86) | (6.57) | (5.50) | (0.51) | (0.59) | (0.46) | (0.17) | (0.01) | — |
Net Current Asset Value |
304.05 | 204.25 | 187.63 | 190.41 | 163.78 | 164.66 | 57.11 | 2.20 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.02 | 0.04 | 0.32 | 0.02 | 0.01 | 0.00 | 0.00 | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
(0.26) | (1.08) | (1.29) | (0.71) | 0.80 | 0.45 | 0.48 | 0.17 | — |
Cash ROIC |
(2.68%) | (15.24%) | (27.08%) | (11.54%) | 0.93% | (6.45%) | (3.33%) | (25.80%) | — |
Accounts Receivable Turnover |
6.68 | 5.56 | 1.64 | 14.05 | 1,018.34 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
2.38 | 0.77 | 0.09 | 0.10 | 0.32 | 0.10 | 0.21 | 0.00 | — |
Inventory Turnover |
8.78 | 4.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
194.93 | 268.04 | 5,428.26 | 3,787.59 | 1,526.84 | 6,449.82 | 2,564.86 | 63,875.00 | — |
Days of Inventory on Hand |
52.01 | 74.56 | 711.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
67.58 | 32.89 | 10.65 | 1.84 | 0.06 | 0.03 | 0.02 | 0.02 | — |
Average Payables |
12.90 | 16.56 | 16.80 | 9.30 | 6.51 | 2.43 | 0.35 | 0.32 | — |
Average Inventory |
3.50 | 2.86 | — | — | — | — | — | — | — |
Average Assets |
469.57 | 321.24 | 246.68 | 203.39 | 175.44 | 115.14 | 30.35 | 1.19 | — |
Average Common Equity |
283.98 | 210.76 | 194.94 | 179.82 | 166.36 | 79.99 | (3.68) | (3.68) | — |
Columns are period end dates